ViroMed announces the launch of a joint study with Biologics Delivery Systems of Cordis Corporation, a Johnson & Johnson Company
ViroMed Co., Ltd. (Seoul), today announced the launch of a joint study with Biologics Delivery Systems Group (BDS of Cordis Corporation, a Johnson & Johnson Company. The study will evaluate the efficacy of VM202 for the treatment of coronary artery disease, using BDS`s NOGA Cardiac Navigation System and the MYOSTAR injection Catheter. Successful completion of this study will facilitate the initiation of the US phase I study, in which VM202, an angiogenic therapeutic product of ViroMed, will be delivered with the NOGA injection system to patient with heart disease without the need for surgical intervention. Approval for this clinical trial in the U.S. is expected during 4th quarter of 2008. Independently, the phase I clinical trial for VM202 for the treatment of peripheral artery disease is ongoing at Minneapolis Heart Institute in the US.
"We are very pleased that a world-renowned company such as Cordis has recognized the potential of VM202 in the treatment of coronary artery diseases," said Sunyoung Kim, CEO of ViroMed. "We hope and anticipate that this initial collaboration will lead to a fruitful and productive partnership between the two companies and will allow us to become a global player in the cardiovascular therapeutic market."
About BDS company: Biologics Delivery Systems (BDS) is a leader in the emerging field of biologics delivery, developing breakthrough technology in cardiac navigation and mapping across multiple disease states and clinical specialties. Biologics Delivery Systems delivery technology is helping to advance the standard of care by enabling physicians to identify and visualize optimal delivery sites, and to precisely target single and multiple treatment sites. This advanced technology is being used to map the heart in more than 17 ongoing clinical trials throughout the world that are investigating the use of adult stem cell and gene therapies.